Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1111/j.1432-2277.2009.00910.x

Type

Journal article

Journal

Transpl Int

Publication Date

10/2009

Volume

22

Pages

1024 - 1027

Keywords

Adolescent, Adult, Aged, Alemtuzumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Death, Female, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Kidney Transplantation, Lymphocyte Count, Lymphocytes, Male, Middle Aged, Recombinant Fusion Proteins, Transplantation Conditioning, Treatment Outcome